CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 7 enrolled
Drug / intervention
Rnalozinedrug
Likely dose
Rnalozine 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01815957
NCT01815957N/ACompleted
CompareCT.gov

Impact of Ranalozine on Coronary Microcirculatory Resistance- A Prospective Single Center Study to Evaluate the Effect of Ranalozine in Microcirculatory Resistance (MICRO Study)

University of New Mexico·interventional·Posted Mar 21, 2013·Updated Dec 26, 2023

In Brief

A clinical study evaluating Rnalozine for Coronary Microcirculation and 3 related conditions. Completed, enrolled 7 participants across 1 site.

Detailed Summary

This study is being done to determine if Ranolazine treatment improves coronary microcirculation function among patients with coronary microcirculation dysfunction. We are also looking to learn if symptomatic improvement of chest pain during treatment with Ranalozine is related to improved coronary microcirculation function.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Microcirculation, Coronary Artery Disease, Myocardial Disease, Ischemia
CountriesUnited States
CollaboratorsGilead Sciences

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMar 21, 2013
Enrollment StartMay 1, 2012
Primary CompletionMar 1, 2016
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 13.3 years ago

Interventions

Rnalozinedrug

. After enrollment in the study, participants will initiate Ranolazine for 4 weeks. The participant's usual anti-anginal medication regimen will be continued unchanged throughout study duration. Patients will receive Ranolazine 500 mg orally twice daily for 1 week, and the dose will be increased to 1,000 mg twice daily for an additional 3 weeks if tolerated.